R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 29.95 PLN -2.28% Market Closed
Market Cap: 692.4m PLN

Wall Street
Price Targets

RVU Price Targets Summary
Ryvu Therapeutics SA

Wall Street analysts forecast RVU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RVU is 75.12 PLN with a low forecast of 48.48 PLN and a high forecast of 104.27 PLN.

Lowest
Price Target
48.48 PLN
62% Upside
Average
Price Target
75.12 PLN
151% Upside
Highest
Price Target
104.27 PLN
248% Upside
Ryvu Therapeutics SA Competitors:
Price Targets
NANOFH
Nanoform Finland Oyj
254% Upside
BANB
Bachem Holding AG
44% Upside
A
Agilent Technologies Inc
22% Upside
ABSI
Absci Corp
235% Upside
300347
Hangzhou Tigermed Consulting Co Ltd
12% Upside
CHEMM
Chemometec A/S
20% Upside
688238
Obio Technology Shanghai Corp Ltd
3% Upside
ERF
Eurofins Scientific SE
4% Upside

Revenue
Forecast

Revenue Estimate
Ryvu Therapeutics SA

For the last 11 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 18%. The projected CAGR for the next 3 years is 25%.

18%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-33%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-37%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RVU's stock price target?
Price Target
75.12 PLN

According to Wall Street analysts, the average 1-year price target for RVU is 75.12 PLN with a low forecast of 48.48 PLN and a high forecast of 104.27 PLN.

What is Ryvu Therapeutics SA's Revenue forecast?
Projected CAGR
25%

For the last 11 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 18%. The projected CAGR for the next 3 years is 25%.

Back to Top